Early SARS-CoV Veredus Laboratories has a track record in rapid development of portable lab-on-chip diagnostics for respiratory viruses, including SARS-CoV, 2019-nCoV, MERS-CoV, and COVID-19, indicating strong capabilities for rapid-response testing deployments that can be positioned to healthcare providers and public health partners.

Omicron Readiness Recent announcements highlight COVID-19 diagnostic tests capable of detecting Omicron and other variants, suggesting ongoing product updates and support for evolving test needs, ideal for sales conversations with clinics, hospitals, and reference labs seeking up-to-date testing solutions.

Saliva and Swab Flex The Extraction-free RT-PCR Suite and ZeroPrep saliva collection options enable streamlined sample collection from saliva or swabs, which can reduce handling steps and costs for customers, presenting a compelling value proposition for point-of-care and centralized labs.

ISO Quality Trust Manufacturing and services align with ISO 9001 and ISO 13485, signaling robust quality management and medical device compliance that can reassure hospital procurement, distributors, and contract manufacturers about reliability and regulatory readiness.

Growing Market Fit With revenue in the low-to-mid millions and a global positioning as a biotechnology diagnostics player, Veredus sits in a competitive space with larger peers; targeted outreach to mid-sized labs, regional distributors, and research institutions can accelerate partnerships and scale adoption.